Minimal Residual Disease in Acute Leukemia:Lessons Learned from Animal Models

  • A. Hagenbeek
  • A. C. M. Martens
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)


Minimal residual disease (MRD) in acute leukemia is defined as the relatively few (1 – 1010) leukemic cells which have survived successful remission-induction chemotherapy. In human acute myelocytic leukemia (AML) there is a significant lack of knowledge on the degree and biological behavior of MRD. However, this is the population of AML cells that determines the failure in the majority of patients:a relapse.


Acute Leukemia Minimal Residual Disease Brown Norway Human Acute Myelocytic Leukemia Bone Marrow Compartment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hagenbeek A, Van Bekkum DW (eds) (1977) Proceedings of an international workshop on Comparative evaluation of the L5222 and the BNML rat leukaemia models and their relevance for human acute leukaemia. Leuk Res 1:75–256Google Scholar
  2. 2.
    Hagenbeek A, Martens ACM (1985) Detection of minimal residual disease in acute leukemia:possibilities and limitations. Eur J Cancer Clin Oncol 21:389–394PubMedCrossRefGoogle Scholar
  3. 3.
    Martens ACM, Hagenbeek A (1985) Detection of minimal disease in acute leukemia using flow cytometry:studies in a rat model for human acute leukemia. Cytometry 6:342–347PubMedCrossRefGoogle Scholar
  4. 4.
    Martens ACM, Johnson RJ, Kaizer H, Hagenbeek A (1984) Characteristics of a monoclonal antibody (Rml24) against acute myelocytic leukemia cells. Exp Hematol 12:667–672PubMedGoogle Scholar
  5. 5.
    Martens ACM, Schultz FW, Hagenbeek A (1987) Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease. Blood 70:1073–1077PubMedGoogle Scholar
  6. 6.
    Van Bekkum DW, Hagenbeek A (1977) Relevance of the BN leukemia as a model for human acute myeloid leukemia. Blood Cells 3:565–572Google Scholar
  7. 7.
    Visser JWM, Martens ACM, Hagenbeek A (1986) Detection of minimal residual disease in acute leukemia by flow cytometry. Ann NY Acad Sci 468:268–276PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • A. Hagenbeek
    • 1
    • 2
  • A. C. M. Martens
    • 1
  1. 1.Radiobiological Institute TNORijswijkThe Netherlands
  2. 2.Dr. Daniel den Hoed Cancer CenterDept. of Hematology and Bone Marrow TransplantationRotterdamThe Netherlands

Personalised recommendations